Preparation of alginate beads for floating drug delivery system: effects of XXXX gas-forming agents.

@entity349 @entity5993 @entity515 @entity14917 @entity16415 @entity3282 @entity8728 @entity1543
Floating beads were prepared from a @entity14917 solution containing @entity16415 or @entity5993 as gas-forming agents. The solution was dropped to 1% @entity3282 solution containing 10% @entity1543 for @entity515 gas and gel formation. The effects of gas-forming agents on bead size and floating properties were investigated. As gas-forming agents increased, the size and floating properties increased. Bead porosity and volume average pore size, as well as the surface and cross-sectional morphology of the beads were examined with @entity349 porosimetry and Scanning Electron Microscopy. @entity5993 significantly increased porosity and pore diameter than @entity16415 . Incorporation of @entity16415 into alginate solution resulted in smoother beads than those produced with @entity5993 . Gel strength analysis indicated that bead strength decreased with increasing gas-forming agent from 9 to 4 N. Beads incorporating @entity16415 exhibited significantly increased gel strength over control and @entity5993 -containing samples. Release characteristics of @entity8728 as a model drug were studied in vitro. Release rate of @entity8728 increased proportionally with addition of @entity5993 . However, increasing weight ratios of @entity16415 did not appreciably accelerate drug release. The results of these studies indicate that @entity16415 is superior to @entity5993 as a gas forming agent in alginate bead preparations. The enhanced buoyancy and sustained release properties of @entity16415 -containing beads make them an excellent candidate for floating drug dosage systems (FDDS).
